Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study: Effect of body weight on pharmacokinetics and clinical outcome

Blood (2025) 146 (Supplement 1): 5812.

https://doi.org/10.1182/blood-2025-5812

Published: 2025

Journal Articles

A single-arm, open-label, multi-center, phase 1b/2 Study to evaluate the safety, efficacy, and cellular pharmacokinetic profile of CTD402 in participants with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL) (TENACITY-01)

Blood (2025) 146 (Supplement 1): 5954.

https://doi.org/10.1182/blood-2025-5954

Published: 2025

Journal Articles

A Phase I, open-label study of CTD402, a universal CD7-targeting CAR T-cell therapy, in patients with relapsed/refractory severe aplastic anemia

Lele Zhang, Ruonan Li, Jing Zhang, Jianping Li, Neng Nie, Xingxin Li, Xiao Yu, Zhexiang Kuang, Liyun Li, Jingyu Zhao, Maria del Rosario, Xiao Shi, Yong Yu, Yali Zhou, Ming Gao, Wengang Ge, Jiangtao Ren, Jan Davidson-Moncada, Jun Shi

Blood (2025) 146 (Supplement 1): 3210.

https://doi.org/10.1182/blood-2025-3210

Published: 2025

Journal Articles

Baseline clinical characteristics of patients with chronic lymphocytic leukemia (CLL) from 11 Latin American countries: A real-world registry analysis

Ana Oliver, Celso Arrais-Rodrigues, Luis Mario Villela Martinez, Macarena Roa, Sofía Rivarola, Lorena Cardozo, Marialejandra Torres Viera, Denisse Castro, Fabiola Valvert, Daniela Trujillo Loaiza, Anelys García Salgado, Victoria Irigoin, Leila Perobelli, Silvana Cigliari, Alana von Glasenapp, Camila Peña, Sally Paredes, Valeria Buccheri, Virginia Lema Spinelli, Augusto Mirolli, Jose Alvarez, Maura Colturato, Ana Ines Landoni, Gislaine Duarte, Marta Zerga, Sabrina ranero Ferrari, Miguel Pavlovsky, Nancy Cristaldo, Laura Fogliatto, Maria Del Rosario Custidiano, Danielle De Farias, Maria Orlova, Fernando Barroso Duarte, Etelvina Macchiavello, Julio Pose Cabarcos, Sérgio Fortier, Julia Laviano, Clarisa Pagano Vilar, Nelson Hamerschlak, Vera Figueiredo, Fernando Pérez-Jacobo, Javier Retamales, Arianna Robles, German Stemmelin, Rosa Rios Jimenez, Henry Quintero, Brady Beltran, Jorge Castillo, Carlos Chiattone, Luis Malpica

Blood (2025) 146 (Supplement 1): 3908.

https://doi.org/10.1182/blood-2025-3908

Published: 2025

Journal Articles

Frontline therapy patterns and outcomes in chronic lymphocytic leukemia: A real-world, multicenter analysis from Latin America.

Celso Arrais-Rodrigues, Ana Oliver, Maria Cugliari, Luis Mario Villela Martinez, Macarena Roa, Lorena Cardozo, Marialejandra Torres Viera, Denisse Castro, Daniela Trujillo Loaiza, Leila Perobelli, Anelys García Salgado, Victoria Irigoin, Sofía Rivarola, Virginia Lema Spinelli, Jose Alvarez, Alana von Glasenapp, Camila Peña, Sally Paredes, Valeria Buccheri, Gislaine Duarte, Maura Colturato, Laura Fogliatto, Ana Ines Landoni, Sabrina ranero Ferrari, Augusto Mirolli, Marta Zerga, Miguel Pavlovsky, Nancy Cristaldo, Maria Del Rosario Custidiano, Fernando Pérez-Jacobo, Danielle De Farias, Maria Orlova, Julio Pose Cabarcos, Fernando Barroso Duarte, Etelvina Macchiavello, Sérgio Fortier, Julia Laviano, Clarisa Pagano Vilar, Nelson Hamerschlak, Vera Figueiredo, Rosa Rios Jimenez, Arianna Robles, Javier Retamales, Melanie Otañez, German Stemmelin, Henry Idrobo, Brady Beltran, Jorge Castillo, Luis Malpica, Carlos Chiattone

Blood (2025) 146 (Supplement 1): 2775.

https://doi.org/10.1182/blood-2025-2775

Published: 2025

Journal Articles

CD7-targeted universal CAR T-cell therapy in relapsed or refractory (R/R) acute myeloid leukemia (AML): Clinical results from CTD401/402 studies

Yong-xian Hu, Xiaoyu Zhu, Heng Mei, Ying Wang, Yali Zhou, Kangqi Bian, Maria del Rosario, Eileen McNulty, Ming Gao, Lu Han, Wengang Ge, Jan Davidson-Moncada, Jiangtao Ren, He Huang

Blood (2025) 146 (Supplement 1): 816.

https://doi.org/10.1182/blood-2025-816

Published: 2025

Journal Articles

CTD402: Allogeneic CAR-t manufacturing that overcomes donor- & process-derived variation with robust clinical activity

Xiaojing Zhang, Liping Zhu, Mengyao Wang, Shuhui Yu, Yu Liu, Mingxi Chen, Yanbo Liu, Yong Yu, Maria del Rosario, Wengang Ge, Jan Davidson-Moncada, Yajin Ni, Jiangtao Ren

Blood (2025) 146 (Supplement 1): 4180.

https://doi.org/10.1182/blood-2025-4180

Published: 2025

Journal Articles

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies

Blood (2025) 146 (10): 1163–1173.

https://doi.org/10.1182/blood.2025028387

Published: 2025

Includes: Supplemental data

Journal Articles

WU-CART-007 (WT-7) Is an Effective Treatment for Adolescent Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL) - Subgroup Analysis of WU-CART-007 1001

Blood (2024) 144 (Supplement 1): 3461.

https://doi.org/10.1182/blood-2024-201998

Published: 2024

Journal Articles

WUC007-03: A Phase 2 Study of Anti-CD7 Allogenic CAR-T Cells (WT-7) in Patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)

Blood (2024) 144 (Supplement 1): 7225.

https://doi.org/10.1182/blood-2024-201825

Published: 2024

Journal Articles

WU-CART-007 (WT-7), an Allogeneic CAR T-Cell Targeting CD7 in Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL): Phase 2 Results

Blood (2024) 144 (Supplement 1): 3450.

https://doi.org/10.1182/blood-2024-202005

Published: 2024

Journal Articles

WUN101-01: First in Human Human (FIH) Phase 1 Study of WU-NK-101 (W-NK1) in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Blood (2024) 144 (Supplement 1): 4257.

https://doi.org/10.1182/blood-2024-201520

Published: 2024

Journal Articles

Microenvironment Immune Cells in Bone Marrow and Lymph Node Measured By Flow Cytometry Have Prognostic Impact on Survival in Nodal Non-Hodgkin T-Cell Lymphoma

Laura Korin, Maria Lucia Fuente, Santiago Cranco, Paola Ochoa, Adriana Vitriu, Evelina Babuin, Olivia Gelo, Luis Ayala, Paula Tempra, Andrea Novoa, Maria Belen Venegas, Anahí Vijnovich Baron, Maria Del Rosario Custidiano, Norma Elisabeth Tartas, Maria Cecilia Foncuberta, Julio Cesar Sanchez Avalos

Blood (2022) 140 (Supplement 1): 11936–11937.

https://doi.org/10.1182/blood-2022-167240

Published: 2022

Journal Articles

Economic Impact Analysis of Treatment-Free Remission in Chronic Myeloid Leukemia Patients with Sustained Deep Molecular Response in the AST-2018 Trial

Blood (2022) 140 (Supplement 1): 5088–5089.

https://doi.org/10.1182/blood-2022-162407

Published: 2022

Journal Articles

Low Percentage of Microenvironment Immune Cells in Bone Marrow and Lymph Node Measured By Flow Cytometry Is Associated with Inferior Overall Survival in Diffuse Large B Cell Lymphoma

Laura Korin, Maria Lucia Fuente, Santiago Cranco, Paola Ochoa, Adriana Vitriu, Evelina Babuin, Anahí Vijnovich Baron, Maria Belen Venegas, Paula Tempra, Andrea Novoa, Norma Elisabeth Tartas, Maria Del Rosario Custidiano, Maria Cecilia Foncuberta, Julio Cesar Sanchez Avalos

Blood (2021) 138 (Supplement 1): 2415.

https://doi.org/10.1182/blood-2021-150839

Published: 2021

Journal Articles

In Pursuit of Surrogate Markers for Treatment-Free Remission in Patients with Chronic Myeloid Leukemia from Argentina Stop Trial

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-141067

Published: 2020

Journal Articles

Bone Marrow Microenvironment Immune Cells Measured By Flow Cytometry Can Predict Survival and Identify a Subgroup in Risk of Early Relapse in Diffuse Large B Cell Lymphoma Patients

Laura Korin, MD, Santiago Cranco, MD, Maria Lucia Fuente, Paola Ochoa, MD, Adriana Vitriu, MD, Evelina Babuin, Maria Belen Venegas, Paula Tempra, Andrea Novoa, Anahí Vijnovich Baron, MD, Fernando Diaz Couselo, MD, Norma Elisabeth Tartas, MD, Maria Del Rosario Custidiano, MD, Maria Cecilia Foncuberta, MD, Julio Cesar Sanchez Avalos, MD

Blood (2020) 136 (Supplement 1): 23.

https://doi.org/10.1182/blood-2020-138881

Published: 2020

Journal Articles

High Level of Successful TKI Discontinuation in Chronic Myeloid Leukemia (CML) Patients: Preliminary Results of AST-Argentina Stop Trial

Blood (2020) 136 (Supplement 1): 3–5.

https://doi.org/10.1182/blood-2020-142416

Published: 2020

Journal Articles

Induction Treatment and Feasibility of Allogeneic Hematopoietic Stem Cell Transplantation in Young Patients (<65 years) with High-Risk Cytogenetic and Secondary Acute Myeloid Leukemia (AML): A Single Center Experience in Argentina with CLAG-M and 7+3

Maria Lucia Fuente, Maria Del Rosario Custidiano, MD, Santiago Cranco, MD, Laura Korin, MD, Paola Ochoa, MD, Adriana Vitriu, MD, Evelina Babuin, Andrea Novoa, Paula Tempra, Maria Belen Venegas, Fernando Diaz Couselo, MD, Norma Elisabeth Tartas, MD, Julio Cesar Sanchez Avalos, MD, Maria Cecilia Foncuberta, MD

Blood (2019) 134 (Supplement_1): 5132.

https://doi.org/10.1182/blood-2019-128491

Published: 2019

Journal Articles

Percentage of Infiltrating T Lymphocytes in Diffuse Large B-Cell Lymphoma Lymph Nodes Measured By Flow Cytometry Predicts Overall Survival and Provides Additional Prognostic Information When Combined with the R-IPI

Laura Korin, MD, Maria Del Rosario Custidiano, MD, Maria Lucia Fuente, Santiago Cranco, MD, Adriana Vitriu, MD, Paola Ochoa, MD, Evelina Babuin, Fernando Diaz Couselo, MD, Anahí Vijnovich Baron, MD, Paula Tempra, Maria Belen Venegas, Andrea Novoa, Norma Elisabeth Tartas, MD, Maria Cecilia Foncuberta, MD, Julio Cesar Sanchez Avalos, MD

Blood (2019) 134 (Supplement_1): 1625.

https://doi.org/10.1182/blood-2019-126193

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study: Effect of body weight on pharmacokinetics and clinical outcome

A single-arm, open-label, multi-center, phase 1b/2 Study to evaluate the safety, efficacy, and cellular pharmacokinetic profile of CTD402 in participants with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL) (TENACITY-01)

A Phase I, open-label study of CTD402, a universal CD7-targeting CAR T-cell therapy, in patients with relapsed/refractory severe aplastic anemia

Baseline clinical characteristics of patients with chronic lymphocytic leukemia (CLL) from 11 Latin American countries: A real-world registry analysis

Frontline therapy patterns and outcomes in chronic lymphocytic leukemia: A real-world, multicenter analysis from Latin America.

CD7-targeted universal CAR T-cell therapy in relapsed or refractory (R/R) acute myeloid leukemia (AML): Clinical results from CTD401/402 studies

CTD402: Allogeneic CAR-t manufacturing that overcomes donor- & process-derived variation with robust clinical activity

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies

WU-CART-007 (WT-7) Is an Effective Treatment for Adolescent Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL) - Subgroup Analysis of WU-CART-007 1001

WUC007-03: A Phase 2 Study of Anti-CD7 Allogenic CAR-T Cells (WT-7) in Patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)

WU-CART-007 (WT-7), an Allogeneic CAR T-Cell Targeting CD7 in Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL): Phase 2 Results

WUN101-01: First in Human Human (FIH) Phase 1 Study of WU-NK-101 (W-NK1) in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Microenvironment Immune Cells in Bone Marrow and Lymph Node Measured By Flow Cytometry Have Prognostic Impact on Survival in Nodal Non-Hodgkin T-Cell Lymphoma

Economic Impact Analysis of Treatment-Free Remission in Chronic Myeloid Leukemia Patients with Sustained Deep Molecular Response in the AST-2018 Trial

Low Percentage of Microenvironment Immune Cells in Bone Marrow and Lymph Node Measured By Flow Cytometry Is Associated with Inferior Overall Survival in Diffuse Large B Cell Lymphoma

In Pursuit of Surrogate Markers for Treatment-Free Remission in Patients with Chronic Myeloid Leukemia from Argentina Stop Trial

Bone Marrow Microenvironment Immune Cells Measured By Flow Cytometry Can Predict Survival and Identify a Subgroup in Risk of Early Relapse in Diffuse Large B Cell Lymphoma Patients

High Level of Successful TKI Discontinuation in Chronic Myeloid Leukemia (CML) Patients: Preliminary Results of AST-Argentina Stop Trial

Induction Treatment and Feasibility of Allogeneic Hematopoietic Stem Cell Transplantation in Young Patients (<65 years) with High-Risk Cytogenetic and Secondary Acute Myeloid Leukemia (AML): A Single Center Experience in Argentina with CLAG-M and 7+3

Percentage of Infiltrating T Lymphocytes in Diffuse Large B-Cell Lymphoma Lymph Nodes Measured By Flow Cytometry Predicts Overall Survival and Provides Additional Prognostic Information When Combined with the R-IPI

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only